NuScale Power experienced a sharp decline in share value following a substantial downgrade from Barclays Capital, which reduced its price target to $15 from $45—a 67% cut—while maintaining an equal weight rating on the stock. The selloff reflects growing caution among major financial institutions regarding the small modular reactor developer's near-term prospects and commercial viability.
The Barclays downgrade follows similar action from Goldman Sachs, which recently trimmed its price target to $20 from $23, signaling broader analyst concern about the company's valuation and execution timeline. These consecutive price target reductions suggest investors and analysts are reassessing assumptions around NuScale's path to profitability and the commercialization of its nuclear technology.
Market participants are monitoring the company closely ahead of its fourth-quarter 2025 earnings report, scheduled for Thursday, which is expected to provide updates on commercial operations progress and key milestones. The earnings release may offer clarity on the company's financial position and the status of its flagship projects, which could influence near-term investor sentiment.